Horizon Therapeutics PLC (NASDAQ:HZNP) was the recipient of unusually large options trading on Monday. Traders bought 2,368 put options on the company. This is an increase of 1,033% compared to the typical volume of 209 put options.
In other Horizon Therapeutics news, CEO Timothy P. Walbert sold 320,174 shares of the stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $28.02, for a total value of $8,971,275.48. Following the sale, the chief executive officer now directly owns 892,483 shares in the company, valued at approximately $25,007,373.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Brian K. Beeler sold 9,969 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $32.51, for a total transaction of $324,092.19. Following the completion of the transaction, the executive vice president now directly owns 89,633 shares of the company’s stock, valued at $2,913,968.83. The disclosure for this sale can be found here. Insiders sold 395,956 shares of company stock valued at $11,118,487 over the last ninety days. Corporate insiders own 4.10% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. NEXT Financial Group Inc boosted its holdings in Horizon Therapeutics by 56.4% during the 2nd quarter. NEXT Financial Group Inc now owns 5,020 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 1,810 shares during the period. New York State Teachers Retirement System bought a new stake in Horizon Therapeutics in the second quarter valued at approximately $55,000. FNY Investment Advisers LLC bought a new stake in Horizon Therapeutics in the second quarter valued at approximately $80,000. First Quadrant L P CA lifted its position in Horizon Therapeutics by 121.7% in the second quarter. First Quadrant L P CA now owns 21,544 shares of the biopharmaceutical company’s stock valued at $518,000 after purchasing an additional 11,827 shares during the last quarter. Finally, Campbell Newman Asset Management Inc. boosted its stake in shares of Horizon Therapeutics by 7.2% during the second quarter. Campbell Newman Asset Management Inc. now owns 32,902 shares of the biopharmaceutical company’s stock valued at $792,000 after purchasing an additional 2,217 shares during the period. Hedge funds and other institutional investors own 88.25% of the company’s stock.
A number of equities analysts have weighed in on HZNP shares. ValuEngine lowered Horizon Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, September 5th. BidaskClub upgraded Horizon Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, November 28th. Zacks Investment Research lowered Horizon Therapeutics from a “buy” rating to a “hold” rating and set a $31.00 price objective for the company. in a report on Tuesday, October 29th. Piper Jaffray Companies set a $33.00 price objective on shares of Horizon Therapeutics and gave the stock a “buy” rating in a research report on Monday, August 26th. Finally, Cowen set a $35.00 target price on shares of Horizon Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 7th. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $33.77.
Shares of NASDAQ:HZNP opened at $31.93 on Tuesday. The stock has a market cap of $6.14 billion, a PE ratio of 17.45, a PEG ratio of 1.97 and a beta of 0.87. The company’s fifty day moving average is $29.83 and its 200 day moving average is $26.53. Horizon Therapeutics has a 52 week low of $17.94 and a 52 week high of $33.21. The company has a quick ratio of 2.23, a current ratio of 2.33 and a debt-to-equity ratio of 0.87.
Horizon Therapeutics (NASDAQ:HZNP) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.14. Horizon Therapeutics had a net margin of 5.25% and a return on equity of 27.71%. The business had revenue of $335.50 million during the quarter, compared to analyst estimates of $330.60 million. During the same period in the prior year, the business posted $0.65 earnings per share. The company’s revenue was up 3.1% on a year-over-year basis. Sell-side analysts anticipate that Horizon Therapeutics will post 1.55 EPS for the current year.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Further Reading: What is required to own or exchange cryptocurrency?
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.